Melanoma Clinical Trials in New York

Showing 1-20 of 311 trials

A Study of Fianlimab, Cemiplimab, and Ipilimumab in People With Melanoma

NCT06594991

The purpose of this study is to test whether the combination of fianlimab, cemiplimab, and ipilimumab is a safe and effective treatment that causes few or mild side effects for locally advanced or metastatic, unresectable, refractory melanoma.

Advanced Melanoma

Memorial Sloan Kettering Cancer Center88 participantsStarted Sep 2024

Los Angeles, California, United States • Stanford, California, United States • Hartford, Connecticut, United States +9 more locations

TERMINATEDPhase 2< 1 mile

Testing Dabrafenib and Trametinib With or Without Hydroxychloroquine in Stage IIIC or IV BRAF V600E/K Melanoma

NCT04527549

This phase II trial investigates how well adding hydroxychloroquine to the standard treatment of dabrafenib and trametinib works to overcome resistance and delay disease progression in treating patients with stage IIIC or IV BRAF V600E/K melanoma. Hydroxychloroquine may cause cell death in tumor cells that rely on a process called "autophagy" for survival. Dabrafenib and trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving hydroxychloroquine together with dabrafenib and trametinib may work better than dabrafenib and trametinib alone to shrink and stabilize the cancer.

Clinical Stage IV Cutaneous Melanoma AJCC v8Locally Advanced MelanomaPathologic Stage IIIC Cutaneous Melanoma AJCC v8+2 more

ECOG-ACRIN Cancer Research Group5 participantsStarted Jun 2021

Anchorage, Alaska, United States • Anchorage, Alaska, United States • Anchorage, Alaska, United States +196 more locations

A Study of Fianlimab, Cemiplimab, and Ipilimumab in People With Melanoma

Testing Dabrafenib and Trametinib With or Without Hydroxychloroquine in Stage IIIC or IV BRAF V600E/K Melanoma

Melanoma Trials in Other Cities

Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain

Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma

Testing Two Different Treatment Schedules of Dabrafenib and Trametinib for Skin Cancer Which Has Spread

Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant Melanoma

A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors

Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery

CD8+ T Cell Imaging During Pre-surgery Immunotherapy in People With Melanoma

Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors

Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial

Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials

A Clinical Trial of PF-08046037 Alone or With Sasanlimab in Patients With Advanced or Metastatic Malignancies

Pembrolizumab in Treating Patients With Desmoplastic Melanoma That Can or Cannot Be Removed by Surgery

Dinaciclib in Treating Patients With Stage IV Melanoma

A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma

Dabrafenib and/or Trametinib Rollover Study

A Study of BI 3810944 in Patients With Advanced Cancer

A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced Cancers

Other Conditions in New York